The review found no eligible studies for this question.
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).
Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
C1 esterase inhibitor showed no clear difference in adverse events (during compared with placebo or active control (moderate certainty).
The review found no eligible studies for this question.
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
The review found no eligible studies for this question.
Berotralstat showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).
It is very uncertain whether C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).
It is very uncertain whether avoralstat changes serious adverse events (during compared with placebo (very low certainty).
Lanadelumab showed no clear difference in serious adverse events (during compared with placebo or active control (low certainty).